Inovio Pharmaceuticals (INO +0.4%) says Phase 1 studies of its SynCon universal H1N1 influenza...

|About: Inovio Pharmaceuticals, Inc. (INO)|By:, SA News Editor

Inovio Pharmaceuticals (INO +0.4%) says Phase 1 studies of its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain. INO adds that this is the first demonstration of a SynCon influenza vaccine achieving a protective immune response rate comparable to a conventional seasonal vaccine for a circulating influenza strain.